Islamabad, Aug 8, 2025: The Drug Regulatory Authority of Pakistan (DRAP) has issued an important voluntary recall notice concerning two popular antibiotic suspensions produced by GlaxoSmithKline Pakistan Ltd (GSK). This precautionary action was prompted by concerns over faulty induction seals that may jeopardize product safety.
Products Affected by the DRAP Antibiotic Recall Pakistan
As per DRAP’s Medical Product Alert No. II/V/08-25-53, the recall impacts the following antibiotic suspensions:
- Amoxil Forte Suspension 250mg (Reg. #000814)
Affected batches: 58
Issue: Faulty cap and induction seal compromising product integrity. - Amoxil Suspension 125mg (Reg. #000508)
Affected batches: 111
Issue: Similar defects in induction sealing and capping.
The compromised seals raise concerns about possible contamination risks and reduced drug effectiveness, making this recall a critical public health measure.
Immediate Actions by DRAP and GSK Pakistan
GSK Pakistan, operating out of F-268, S.I.T.E Karachi, proactively alerted DRAP after identifying the defective packaging. Following this, DRAP directed the prompt removal of all impacted batches from circulation to protect consumers nationwide.
Pharmacies, hospitals, and distributors throughout Pakistan have been officially instructed to quarantine and return the affected stock. Healthcare professionals and regulatory teams are urged to act swiftly in enforcing this recall to safeguard public health.
How to Respond If You Have These Antibiotics
Consumers and healthcare providers are strongly advised to check the batch numbers against the comprehensive list published by DRAP on August 5, 2025. Anyone holding Amoxil 125mg or 250mg suspensions from the recalled batches should immediately cease use and return the products to their nearest pharmacy.
Read More: Punjab Imposes Sanitation Fee for All Residents
For reporting or further assistance, DRAP’s complaint portal is available to the public for swift communication regarding these concerns.
